Shaping the Future of Oncology for Patients l Exelixis
Exelixis is an oncology-focused biotech company innovating cancer treatments for life. Find out how we're dedicated to giving more patients hope for the future.
Careers
Exelixis accepts no responsibility for any …Pipeline
Clinical trials & pipeline. We are …Inside Exelixis
Exelixis is on a mission to help cancer patients recover stronger and live …
Treating Cancer
As a leading cause of death worldwide, cancer accounts for almost 10 million …
Innovating R&D
Clinical trials and pipeline. Pipeline expansion is a key driver of our growth …
Creating Impact
Supporting nonprofit organizations is a critical component of how we bring our …
Investors & News
Exelixis is expanding its global …Our Story
The Exelixis story began in 1994 when our prominent team of founding scientists …
Employee Experience
Exelixis offers purpose-driven career opportunities in an entrepreneurial …
Diversity, Equity & Inclusion
Exelixis’ DEI Advisory Committee is a select group of self-nominated employees …
Q3, Exelixis
✕About this result- This title and these news articles are related to your search term(s).
- Articles come from a variety of sources across the web.
- Titles are algorithmically generated based on content related to your search term(s).
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Cancer Clinical Trials and Pipeline l Exelixis
Exelixis is a biopharmaceutical company developing and partnering on compounds for various cancers. See the phase and phase 1 trials of cabozantinib, zanzalintinib, XB002, …
Our Medicines for Cancer Patients l Exelixis
Exelixis is a biopharmaceutical company that develops and commercializes cancer medicines based on data and science. Learn about its products, such as CABOMETYX, …
Exelixis - Wikipedia
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Wikipedia · Text under CC-BY-SA license- Estimated Reading Time: 6 mins
Interesting reads - Exelixis
Powered by Microsoft StartExelixis, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts …
1 day ago · Exelixis delivered a significant beat with revenue hitting US$540m and statutory EPS reaching US$0.40, both beating estimates by more than 10%. Earnings are an important time …
FDA approves cabozantinib for differentiated thyroid cancer
Sep 22, 2021 · Cabozantinib is a drug developed by Exelixis, Inc. for adult and pediatric patients with locally advanced or metastatic differentiated thyroid cancer that has …
- People also ask
Exelixis Announces U.S. Food and Drug Administration (FDA) …
Aug 6, 2024 · Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and …
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 …
Jan 25, 2024 · ALAMEDA, Calif. -- (BUSINESS WIRE)--Jan. 25, 2024-- Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from CONTACT-02, a phase 3 pivotal study …
Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges …
3 days ago · Exelixis is a biotechnology company based in Alameda, California that aims to be a best-in-class genitourinary [GU] and gastrointestinal [GI] oncology firm. Its portfolio includes …
